HC Wainwright Has Weak Forecast for Precigen FY2026 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Investment analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Precigen in a report issued on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of ($0.01) for the year, down from their previous estimate of $0.01. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.62 EPS.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.

Precigen Trading Up 3.7 %

Shares of NASDAQ PGEN opened at $1.39 on Friday. The stock has a market capitalization of $407.09 million, a PE ratio of -2.53 and a beta of 1.65. The stock’s fifty day simple moving average is $0.94 and its two-hundred day simple moving average is $1.06. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93.

Institutional Trading of Precigen

A number of institutional investors have recently made changes to their positions in PGEN. Iridian Asset Management LLC CT boosted its position in shares of Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after purchasing an additional 1,706,815 shares in the last quarter. LexAurum Advisors LLC boosted its position in shares of Precigen by 151.9% in the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 417,055 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Precigen by 12.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after purchasing an additional 130,500 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Precigen by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after purchasing an additional 127,467 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.